Recently, ZonhonBio successfully completed a Phase I clinical trial for its "ZHB103 Injection" and obtained the Phase I Clinical Trial Summary Report. The study was titled: "A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZHB103 Injection in Healthy Subjects." The Phase I clinical results demonstrated that ZHB103 Injection exhibited a favorable safety and tolerability profile within the tested dose range, with no serious adverse events reported among any trial participants. The recommended Phase II dose was determined, and the anticipated study objectives were achieved. Based on the positive Phase I findings, ZonhonBio plans to initiate subsequent clinical studies in 2026 to further investigate the safety and efficacy of ZHB103 Injection.

ZonhonBio is dedicated to the systematic development of humanized KKS system genetically engineered drugs, comprehensively exploring the potential application value and drug development potential of each constituent component and its genetically engineered derivatives. Positioned as an innovative explorer in central nervous system (CNS) drugs, the company aims to provide more effective therapeutic approaches for patients with CNS disorders.